Vivian C. W. Fung

Vivian C. W. Fung

Auto-generated profile, based on publicly available information

Vivian C. W. Fung

BC Children’s Hospital Research Institute, University of British Columbia, Vancouver, BC V5Z 4H4, Canada

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
NDNicholas A. J. Dawson
Nicholas A. J. Dawson
IRIsaac Rosado-Sánchez
Isaac Rosado-Sánchez
GNGerman E. Novakovsky
German E. Novakovsky
VFVivian C. W. Fung
Vivian C. W. Fung
QHQing Huang
Qing Huang
MLMegan K. Levings
Megan K. Levings
Comparison of 10 co-receptor variant CARs revealed a requirement for CD28wt for optimal suppression by human regulatory T cells.

10 August 2023 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
JSJustin A. Spanier
Justin A. Spanier
VFVivian Fung
Vivian Fung
CWChristine M. Wardell
Christine M. Wardell
MAMohannad H. Alkhatib
Mohannad H. Alkhatib
YCYixin Chen
Yixin Chen
MLMegan K. Levings
Megan K. Levings
Adoptive immunotherapy with Tregs is a promising approach for preventing or treating type 1 diabetes. Islet antigen–specific Tregs have more potent therapeutic effects than polyclonal cells, but their low frequency is a barrier for clinical application. To generate Tregs that recognize islet antigens, we engineered a chimeric antigen receptor (CAR) derived from a monoclonal antibody with specificity for the insulin B chain 10–23 peptide presented in the context of the IAg7 MHC class II allele present in NOD mice. Peptide specificity of the resulting InsB-g7 CAR was confirmed by tetramer staining and T cell proliferation in response to recombinant or islet-derived peptide. The InsB-g7 CAR redirected NOD Treg specificity such that insulin B 10–23–peptide stimulation enhanced suppressive function, measured via reduction of proliferation and IL-2 production by BDC2.5 T cells and CD80 and CD86 expression on dendritic cells. Cotransfer of InsB-g7 CAR Tregs prevented adoptive transfer diabetes by BDC2.5 T cells in immunodeficient NOD mice. In WT NOD mice, InsB-g7 CAR Tregs prevented spontaneous diabetes. These results show that engineering Treg specificity for islet antigens using a T cell receptor–like CAR is a promising therapeutic approach for the prevention of autoimmune diabetes.

9 October 2023 in JCI Insight
Verified
Journal Article
Open access
PDF file
IRIsaac Rosado-Sánchez
Isaac Rosado-Sánchez
MHManjurul Haque
Manjurul Haque
KSKevin Salim
Kevin Salim
MSMadeleine Speck
Madeleine Speck
VFVivian C.W. Fung
Vivian C.W. Fung
MLMegan K. Levings
Megan K. Levings
Tregs expressing chimeric antigen receptors (CAR-Tregs) are a promising tool to promote transplant tolerance. The relationship between CAR structure and Treg function was studied in xenogeneic, immunodeficient mice, revealing advantages of CD28-encoding CARs. However, these models could underrepresent interactions between CAR-Tregs, antigen-presenting cells (APCs), and donor-specific Abs. We generated Tregs expressing HLA-A2–specific CARs with different costimulatory domains and compared their function in vitro and in vivo using an immunocompetent model of transplantation. In vitro, the CD28-encoding CAR had superior antigen-specific suppression, proliferation, and cytokine production. In contrast, in vivo, Tregs expressing CARs encoding CD28, ICOS, programmed cell death 1, and GITR, but not 4-1BB or OX40, all extended skin allograft survival. To reconcile in vitro and in vivo data, we analyzed effects of a CAR encoding CD3ζ but no costimulatory domain. These data revealed that exogenous costimulation from APCs can compensate for the lack of a CAR-encoded CD28 domain. Thus, Tregs expressing a CAR with or without CD28 are functionally equivalent in vivo, mediating similar extension of skin allograft survival and controlling the generation of anti–HLA-A2 alloantibodies. This study reveals a dimension of CAR-Treg biology and has important implications for the design of CARs for clinical use in Tregs.

20 August 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
CWChristine M. Wardell
Christine M. Wardell
VFVivian C. W. Fung
Vivian C. W. Fung
ECEleanor Chen
Eleanor Chen
MHManjurul Haque
Manjurul Haque
DTDavid F. H. Tan
David F. H. Tan
MLMegan K. Levings
Megan K. Levings
Regulatory T cells (T reg cells) have potential as a cell-based therapy to prevent or treat transplant rejection and autoimmunity. Using a human leukocyte antigen (HLA)–A2-specific chimeric antigen receptor (A2-CAR), we previously showed that adoptive transfer of A2-CAR T reg cells can limit anti–HLA-A2 alloimmunity. However, it was unknown whether A2-CAR T reg cells could also limit immunity to autoantigens. Using a model of HLA-A2 + islet transplantation into immunodeficient nonobese diabetic mice, we investigated whether A2-CAR T reg cells could control hyperglycemia induced by diabetogenic BDC2.5 effector T cells. In mice transplanted with HLA-A2 + islets, A2-CAR T reg cells reduced BDC2.5 T cell engraftment, proliferation, and cytokine production and protected mice from diabetes. Islet tolerance was systemic, including protection of the HLA-A2 negative endogenous pancreas. Treated mice remained euglycemic even after removal of the HLA-A2 + islet graft and A2-CAR T reg cells. Thus, A2-CAR T reg cells can induce linked suppression and long-lasting tolerance to a distinct autoimmune antigen. Tolerance to the autoantigen does not require A2-CAR T reg persistence, indicating the presence of infectious tolerance. Overall, these data demonstrate that A2-CAR T reg cells have potential therapeutic use to simultaneously control both allo- and autoimmunity in islet transplantation.

13 June 2025 in Science Advances
Verified
Journal Article
Open access
DBDominic A. Boardman
Dominic A. Boardman
SMSonya Mangat
Sonya Mangat
JGJana K. Gillies
Jana K. Gillies
LLLorna Leon
Lorna Leon
VFVivian C. W. Fung
Vivian C. W. Fung
MLMegan K. Levings
Megan K. Levings
Regulatory T cell (T reg cell) therapy has been transformed through the use of chimeric antigen receptors (CARs). We previously found that human T reg cells minimally produce IL-10 and have a limited capacity to control innate immunity compared to type 1 regulatory T cells (T r 1 cells). To create “hybrid” CAR T reg cells with T r 1 cell-like properties, we examined whether the PDCD1 locus could be exploited to endow T reg cells with CAR-regulated IL-10 expression. CRISPR-mediated PD1 deletion increased CAR T reg cell activation, and knock-in of IL10 under control of the PD1 promoter resulted in CAR-induced IL-10 secretion. IL10 knock-in improved CAR T reg cell function, as determined by increased suppression of dendritic cells and alloantigen- and islet autoantigen–specific T cells. In vivo, IL10 knock-in CAR T reg cells were stable, safe, and suppressed dendritic cells and xenogeneic graft-versus-host disease. CRISPR-mediated engineering to simultaneously remove an inhibitory signal and enhance a suppressive mechanism is a previously unexplored approach to improve CAR T reg cell potency.

23 May 2025 in American Journal of Transplantation
Verified
Journal Article
Open access
SCSarah J. Colpitts
Sarah J. Colpitts
SJSinthuja Jegatheeswaran
Sinthuja Jegatheeswaran
AOAmanda Oakie
Amanda Oakie
SMSiavash Mashhouri
Siavash Mashhouri
NSNadia Sachewsky
Nadia Sachewsky
SCSarah Q. Crome
Sarah Q. Crome
Group 2 innate lymphoid cells (ILC2s) that produce IL-10 (IL-10+ILC2s) have demonstrated regulatory and tissue-protective properties in murine studies, but preclinical studies are lacking that explore the potential of human IL-10+ILC2s as a tolerance-promoting cell therapy for transplantation or autoimmunity. Here, we investigated whether human IL-10+ILC2s could enhance islet function and prevent allograft rejection in humanized mouse models of islet transplantation. In vitro, human IL-10+ILC2s did not display cytotoxicity towards allogeneic deceased-donor islets or stem cell-derived islet-like cells, and co-transplantation with IL-10+ILC2s significantly improved glucose control post-transplantation. Allogeneic IL10+ILC2s directly inhibited T cell-mediated cytotoxicity against islet-like cells in vitro, and in an antigen-specific transplant rejection model, prevented T cell-mediated rejection of deceased donor islet grafts. Effects were greater with allogeneic IL-10+ILC2s, as autologous cells did not inhibit T cell IFN-γ production or cytotoxic activity in vitro, and were not sufficient to prevent islet rejection in vivo.Collectively, these studies provide proof-of-principle that human IL-10+ILC2s have therapeutic potential for islet transplantation and type 1 diabetes, and support their use as an allogeneic regulatory cell therapy.